Michael Barbella, Managing Editor12.09.23
Resources—both human and capital—drove the bulk of MPO website traffic this past week.
Medtronic, Nissha Medical Technologies, and Edwards Lifesciences amassed pageviews for their respective monetary moves, while Olympus and Agiliti enticed cybervisitors to the site with their personnel proclamations.
Medtronic became content king by terminating its $738 million agreement to acquire EOFlow due to multiple agreement breaches. EOFlow manufactures the EOPatch, a tubeless, wearable, and fully disposable insulin delivery device that delivers insulin with high accuracy and reliability, while minimizing the risk of insulin occlusion. The acquisition was first announced in May 2023 but Rival insulin pump maker Insulet claimed three months later in a lawsuit filing that EOFlow's EOPatch violated three of the patents for its Omnipod pump and that the designs are "practically identical."
Nissha Medical made its own cyberwaves via its deal to acquire the majority equity of Isometric Micro Molding, a transaction that is expected to wrap up by year's end. Specifically, the company will take a majority stake in Isometric Intermediate LLC, which owns the Isometric group of companies. Isometric Intermediate is a contract design/development and manufacturing organization that designs, develops, and manufactures minimally invasive surgical instruments and medical wearables.
Ranking third was Edwards Lifesciences' announcement about the planned spinoff of its critical care business by the end of next year. The move reportedly will help the company sharpen its focus on transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and Surgical technologies—as well as make new investments in interventional heart failure technologies.
Olympus Corporation and Agiliti, meanwhile, gained favor with MPO loyalists for naming a new chief medical officer and new (old) CEO.
Medtronic, Nissha Medical Technologies, and Edwards Lifesciences amassed pageviews for their respective monetary moves, while Olympus and Agiliti enticed cybervisitors to the site with their personnel proclamations.
Medtronic became content king by terminating its $738 million agreement to acquire EOFlow due to multiple agreement breaches. EOFlow manufactures the EOPatch, a tubeless, wearable, and fully disposable insulin delivery device that delivers insulin with high accuracy and reliability, while minimizing the risk of insulin occlusion. The acquisition was first announced in May 2023 but Rival insulin pump maker Insulet claimed three months later in a lawsuit filing that EOFlow's EOPatch violated three of the patents for its Omnipod pump and that the designs are "practically identical."
Nissha Medical made its own cyberwaves via its deal to acquire the majority equity of Isometric Micro Molding, a transaction that is expected to wrap up by year's end. Specifically, the company will take a majority stake in Isometric Intermediate LLC, which owns the Isometric group of companies. Isometric Intermediate is a contract design/development and manufacturing organization that designs, develops, and manufactures minimally invasive surgical instruments and medical wearables.
Ranking third was Edwards Lifesciences' announcement about the planned spinoff of its critical care business by the end of next year. The move reportedly will help the company sharpen its focus on transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and Surgical technologies—as well as make new investments in interventional heart failure technologies.
Olympus Corporation and Agiliti, meanwhile, gained favor with MPO loyalists for naming a new chief medical officer and new (old) CEO.